ET Pharma’s Post

Alert: German Pharmaceutical Industry Association warns of potential API shortages. As per yesterday’s Euro news German pharmaceutical industry association (BPI - Bundesvergand der Pharmazeutischen Industrie) has raised a red flag over possible drug shortages following recent tightening of espionage laws in China. As China plays a crucial role in the global supply chain for active pharmaceutical ingredient (API), these new regulations could impact the availability of essential medications. Several German states have now cancelled routine quality-control trips to China by their inspectors as they're concerned, they could fall foul of the over tightened espionage law. The states say they can no longer guarantee the safety of their inspectors on visits to Chinese pharmaceutical factories. Some API certificates have already expired or near expiry. In Germany, most of API, especially, antibiotics import from China, according to BPI. Several foreign organisations have requested for more clarity over revisions to the law, particularly on what data is safe for foreign businesses to collect. Source of Information: Euro news. Key Impacts: Regulatory Impact: Could affect API export because of API certification expiry. Supply Chain Risks: Potential shortages may lead to delays and increased costs. Strategic Response: Companies need to explore alternative sourcing and enhance supply chain resilience. #PharmaIndustry #API #APISupply #China #Healthcare #GlobalHealth #Export #Import #Pharmaceuticals #IndustryAlert #SupplyChain #Espionage #Anti #Bill #Germany #Europe #Import

Key challenges of medication delivery to Kazakhstan. Part II. Where to contract pharmacy transportation from? Popular options include India, China, and the European Union — each offering distinct advantages. Importing from India India is known as the “pharmacy of the world,” and with good reason. It is the leading producer of generic medications, and its pharmaceutical industry adheres to stringent international quality standards. Contracting from India means access to affordable, high-quality drugs that meet global regulatory requirements. The country has a well-established pharmaceutical export infrastructure, meaning it’s no stranger to large-scale international deliveries. However, the key challenge lies in the distance and the sometimes lengthy customs process, which can delay shipments unless handled by experienced operators. Importing from China China is another major player in pharmaceutical exports, especially for active pharmaceutical ingredients. China is an appealing option if you’re looking to source bulk medications at competitive prices. The country has strong logistics networks and deep experience in global supply chain management, making it a reliable shipment source. Importing from the European Union Regarding contracting pharmacy transportation from Europe, Germany and Czechia are reliable sources. Both countries have highly advanced pharmaceutical industries, known for their quality control standards and adherence to EU regulations. Additionally, both countries have well-established logistics networks, allowing for seamless transportation routes to Kazakhstan. Part I https://lnkd.in/eFWR_FGk

Will pakistan be able to increase their pharmaceutical share to the 1/3rd of indian pharmaceutical? Major challenges includes: - #DRAP lack of commercial understanding hinders exports - #Liquidity issues restrict #international_marketing - Protective duty on APIs makes Pakistani medicines uncompetitive - Unstable supply chain and raw material procurement - Government support crucial for #growth What one strategy would you implement to address regulatory, liquidity, and supply chain challenges? #pharmaceuticalexports #Pakistan #govtofpunjab #healthcare

Key Update on the Pricing of Pharmaceutical Products and Its Impacts in Turkiye The recent amendment to the Decree on the Pricing of Pharmaceutical Products in Turkey establishes a fixed exchange rate of the Euro to the Turkish Lira for the entire year of 2024. This decision aims to maintain price stability for medicines and improve access to healthcare services. While it provides financial planning ease for manufacturers and importers, it may also increase costs for imported materials. The long-term economic effects of this decision need careful monitoring. Overall, this amendment requires a balanced approach from both the government and industry representatives. For more details please click the link! https://lnkd.in/d67tqHrX #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

https://lnkd.in/d2HK5xW7 India's pharmaceutical sector stands at a crossroads. The journey toward self-reliance in API production is critical, not only for the stability of the industry but also for ensuring that India remains the world's "pharmacy" in both good times and bad.

Till late 80’s and 90’s India used to produce 70-80% of pharmaceuticals raw material required by its pharmaceutical industry. Then came cheap Chinese API (Active pharmaceutical ingredient), due to incentives and modern technology by Chinese government. Slowly all small and medium companies died, since they cannot match the price. Till 2004-05 when pharma industry become fully dependent on these Chinese raw materials, they increase the price up to 5 times, covering earlier losses. Today India import 80-90% of API from China and they drive the prices. It will take decades for India to rebuild this manufacturing again. Similarly till 2020 Chinese EV market share in Europe was 1.9%, which in 2024 become 14.1%, again same strategy, cheap car with heavy subsidy from government, it’s not fair for European companies. We can clearly see the pattern. If it will not stop slowly they will kill this market as well, so I am happy at least EU union decided to go ahead with tariff implementation plan for Chinese EV.

Why is FIFO method important? The FIFO (First In, First Out) method is a crucial aspect in any industry, especially in the pharmaceutical industry. This method ensures the safety and compliance of the products and the consumers. FIFO is a system where the first items that come into the inventory are the first ones that go out. Being aware of the sensitivity of the products offered for sale in the health sector, Elbi Pharmaceutical Warehouse uses the FIFO (First in First Out) inventory system in its warehouses for the quality and reliability of the products it offers for sale and each product is bar-coded both at the entrance to the warehouse and during shipment. Thus, the product in the warehouse under no circumstances will not wait for a long time and the shelf life of the products is also provided. 40+YEARS' EXPERIENCE & QUALITY AROUND ALL WORLD - - - - - #byelbipharma #byelbisupmax #nutritionalsupplements #ghana #somali #libya #yemen #qatar #djibouti #nigeria #kenya #albania #makedonia #dubai #pakistan #pharmacy #pharmaceuticalexport #pharmaceuticalswholesaler #pharmaceuticalwarehouse #medicalequipment #internationalexport #nutrients #vitaminsupplements #pharmacist #exportmanager #parallelexport

Pakistan's pharmaceutical industry is significantly contributing to GDP, achieving sales of Rs. 916 billion (USD 3.3 billion) in FY24, marking a 22% year-on-year growth[1][2]. This sector is organized and led by skilled professionals, yet it faces challenges in export facilitation. The government must prioritize collaboration with the industry and reduce heavy taxes on APIs and machinery to foster growth[3][4]. Unlike India and Bangladesh, which have FDA-approved plants, Pakistan needs to enhance its regulatory framework and seek international consultancy for FDA approvals to boost its top manufacturers[5]. DRAP Consultancy Services ServicesDrugregulatory Drugregulatory Export PakZulfiqar OmerSyed Haider AliDr.Aman Ullah Khan Sources [1] Price deregulation: Pakistan's pharma sector sales hit $3.3bn in FY24, 22 ... https://lnkd.in/eWUCdFPJ [2] Pakistan's pharmaceutical industry sees record 22% growth in FY24 https://lnkd.in/enzEaVkq [3] [PDF] PAKSTAN PHARMACEUTICAL SECTOR REPORT - VIS Credit Rating https://lnkd.in/eyznwSKw [4] Pharmaceutical industry in Pakistan - Wikipedia https://lnkd.in/ecfAD7uB [5] Unleashing the Potential of Pharmaceuticals in Pakistan https://lnkd.in/e4-UPFQb [6] [PDF] Pharmaceutical Industry - Pacra.com https://lnkd.in/eRZZuKnJ [7] [PDF] Pharmaceutical - ICAP https://lnkd.in/euK5N8-C [8] Pharmaceuticals - Pakistan | Statista Market Forecast https://lnkd.in/eh6iAr5h .

In my latest article published in the Daily Observer, I explore both the promising prospects and the current challenges shaping the future of the Pharmaceutical sector. Read the full article to discover the key factors driving this transformation. https://lnkd.in/g5-THVHD

India's pharmaceutical industry, once hailed as the 'world's pharmacy', is facing intense scrutiny and regulatory action due to widespread non-compliance and export of unsafe medications. Recent inspections by CDSCO have revealed alarming lapses in quality control, leading to the closure of over 36% of drug manufacturing units. This crackdown comes after international concerns were raised following tragic incidents involving contaminated Indian-made cough syrups in Gambia, Uzbekistan, and Cameroon. With India's pharmaceutical sector facing reputational damage and global scrutiny, the government has implemented stringent regulatory measures to ensure drug safety and quality. While progress has been made, sustained vigilance and transparency are essential to rebuild trust in Indian pharmaceuticals worldwide. The industry's ability to meet global standards is under scrutiny, and robust quality control measures are paramount to prevent future tragedies and safeguard public health. #IndiaPharma #DrugSafety #QualityControl #GlobalHealth Read more at... https://lnkd.in/d5H_jpEh